VERIGRAFT is a pioneering biotechnology company based in Gothenburg, Sweden, specializing in personalized tissue-engineered transplants. Established in 2004, the company has its roots in the Karolinska Institute and focuses on regenerative medicine. VERIGRAFT aims to revolutionize transplantation by developing biological grafts that are tailored to each patient, thereby eliminating the need for lifelong immunosuppression and reducing associated risks such as infections and cancer. 

The company's innovative approach involves creating personalized tissues and organs that the patient's immune system recognizes as its own, effectively preventing rejection. This technology has the potential to transform treatments for various conditions, including cardiovascular and neurological diseases. VERIGRAFT's research and development pipeline includes projects focused on veins, arteries, nerves, and heart valves.